{
    "clinical_study": {
        "@rank": "33725", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give calanolide A to\n      HIV-infected adults who have not used anti-HIV drugs in the past."
        }, 
        "brief_title": "The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive (+)-calanolide A or placebo for 21 days. All patients may\n      elect to receive an open-label, 3-month course of approved retroviral therapy (up to\n      triple-drug therapy) to be selected by, and administered under the care of, the patients'\n      physicians. If the patient has no insurance coverage or does not wish to utilize his/her\n      insurance for anti-HIV medications, Sarawak MediChem Pharmaceuticals will provide these\n      medications at no charge for up to 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients may be eligible for this study if they:\n\n          -  Are at least 18 years old.\n\n          -  Agree to use effective methods of birth control during the study.\n\n          -  Have a CD4 cell count of 200 cells/mm3 or more.\n\n          -  Have HIV levels of 5000 copies/ml or more.\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Have abnormal blood tests.\n\n          -  Have had a reaction to study medication.\n\n          -  Have a history of opportunistic (AIDS-related) infection or cancer.\n\n          -  Are being treated for active pulmonary tuberculosis.\n\n          -  Have a fever of 39 degrees C or more within 14 days of beginning study treatment.\n\n          -  Are unable to take medications by mouth.\n\n          -  Have an abnormal chest X-ray or ECG within 30 days of beginning study treatment.\n\n          -  Have hepatitis, hemophilia, or other blood disorder.\n\n          -  Have significant heart, stomach, intestinal, liver, nerve, or kidney problems.\n\n          -  Have a condition which may affect ability to participate in this study, such as drug\n             or alcohol abuse or a serious mental disorder.\n\n          -  Have taken anti-HIV drugs in the past.\n\n          -  Are taking certain medications.\n\n          -  Have had a blood transfusion within the 3 months prior to entering the study.\n\n          -  Have had radiation or chemotherapy within 16 days before the screening visit or plan\n             to receive such treatment during the study.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "16", 
        "firstreceived_date": "April 20, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005120", 
            "org_study_id": "297B", 
            "secondary_id": "57CL-0001"
        }, 
        "intervention": {
            "intervention_name": "Calanolide A", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Calanolide A", 
                "Anti-HIV Agents"
            ]
        }, 
        "keyword": [
            "CD4 Lymphocyte Count", 
            "Biological Markers", 
            "Anti-HIV Agents", 
            "Viral Load", 
            "Pharmacokinetics", 
            "calanolide A"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "331813405"
                    }, 
                    "name": "South Florida Bioavailability Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60610"
                    }, 
                    "name": "Chicago Ctr for Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "The CORE Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Anderson Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15221"
                    }, 
                    "name": "Anderson Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29206"
                    }, 
                    "name": "Burnside Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "775550835"
                    }, 
                    "name": "Univ of Texas Med Branch"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase IB Study to Evaluate the Safety, Pharmacokinetics, and Effects of (+)-Calanolide A on Surrogate Markers in HIV-Positive Patients With No Previous Antiretroviral Therapy", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005120"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sarawak MediChem Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2000", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2001"
    }, 
    "geocoordinates": {
        "Anderson Clinical Research": "40.441 -79.996", 
        "Burnside Clinic": "34.001 -81.035", 
        "Chicago Ctr for Clinical Research": "41.878 -87.63", 
        "South Florida Bioavailability Clinic": "25.789 -80.226", 
        "The CORE Ctr": "41.878 -87.63", 
        "Univ of Texas Med Branch": "29.301 -94.798"
    }
}